Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$52.08
-4.1%
$50.63
$21.34
$58.40
$4.15B-0.151.06 million shs881,281 shs
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$12.50
+0.1%
$12.50
$8.74
$12.51
$799.18M1.391.45 million shs3.07 million shs
Merus N.V. stock logo
MRUS
Merus
$63.26
+3.0%
$52.47
$33.19
$63.43
$4.38B1733,967 shs1.06 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$9.46
-1.9%
$9.52
$8.01
$23.10
$2.46B0.63.63 million shs3.13 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%+0.99%-5.14%+38.40%+92.32%
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.00%0.00%0.00%0.00%+27.89%
Merus N.V. stock logo
MRUS
Merus
0.00%+16.07%+20.29%+46.91%+11.87%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%-4.83%-4.31%-14.84%-55.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.7714 of 5 stars
3.51.00.04.73.30.80.0
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.8984 of 5 stars
1.00.00.04.50.01.70.6
Merus N.V. stock logo
MRUS
Merus
2.1665 of 5 stars
3.61.00.00.02.62.50.0
Organon & Co. stock logo
OGN
Organon & Co.
4.8103 of 5 stars
3.33.01.73.71.83.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$82.5058.41% Upside
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.00
Hold$12.25-1.96% Downside
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6433.79% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.50
Moderate Buy$18.0090.27% Upside

Current Analyst Ratings Breakdown

Latest CDMO, AKRO, MRUS, and OGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$63.00 ➝ $64.00
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/22/2025
Organon & Co. stock logo
OGN
Organon & Co.
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/19/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/15/2025
Organon & Co. stock logo
OGN
Organon & Co.
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.00
5/13/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $78.00
5/8/2025
Merus N.V. stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/5/2025
Organon & Co. stock logo
OGN
Organon & Co.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.00
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Inline
4/28/2025
Merus N.V. stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$139.91M5.71$0.15 per share80.92$3.02 per share4.14
Merus N.V. stock logo
MRUS
Merus
$36.13M121.18N/AN/A$9.46 per share6.69
Organon & Co. stock logo
OGN
Organon & Co.
$6.29B0.39$4.93 per share1.92$1.83 per share5.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.883.282.530.9811.92%227.43%7.34%8/5/2025 (Estimated)

Latest CDMO, AKRO, MRUS, and OGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$0.95N/AN/AN/AN/AN/A
8/7/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.93N/AN/AN/A$1.55 billionN/A
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/12/2025Q1 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$1.01$0.90+$1.91$0.90N/AN/A
5/1/2025Q1 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.85%N/A2.78%N/A

Latest CDMO, AKRO, MRUS, and OGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.8%5/12/20255/12/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.03
16.80
16.80
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.58
1.30
0.92
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86
Organon & Co. stock logo
OGN
Organon & Co.
16.49
1.67
1.15

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
97.16%
Merus N.V. stock logo
MRUS
Merus
96.14%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.05%
Merus N.V. stock logo
MRUS
Merus
4.57%
Organon & Co. stock logo
OGN
Organon & Co.
1.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.72 million74.08 millionOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
32063.96 million62.01 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.96 million254.86 millionNot Optionable

Recent News About These Companies

OGN SECURITIES NEWS: Did Organon & Co. ...
TUESDAY INVESTOR DEADLINE: Organon & Co. ...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$52.08 -2.25 (-4.14%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$52.74 +0.66 (+1.27%)
As of 07/18/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Avid Bioservices stock logo

Avid Bioservices NASDAQ:CDMO

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Merus stock logo

Merus NASDAQ:MRUS

$63.26 +1.82 (+2.96%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$63.24 -0.02 (-0.04%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$9.46 -0.18 (-1.87%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$9.47 +0.01 (+0.10%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.